Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 65 for:    "BGB-A317"

Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03358875
Recruitment Status : Active, not recruiting
First Posted : December 2, 2017
Last Update Posted : May 19, 2021
Sponsor:
Information provided by (Responsible Party):
BeiGene

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : December 30, 2021
Estimated Study Completion Date : December 30, 2021